News Genmab A/S Nasdaq

Stocks

GMAB

US3723032062

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 01:30:00 09/07/2026 am IST			5-day change	1st Jan Change
29.54 ^USD	+1.23%		+6.87%	-4.09%

10:24am	Nordic stocks in North America: Ericsson fell 0.7 percent	FW
07/07	Exchange-Traded Funds Lower, Equity Futures Mixed Amid Caution Over Chip Sector Outlook	MT

All News

Mentions Relevance

07/07	Genmab Secures EU Approval for Drug Combination Intended for Relapsed or Refractory Follicular Lymphoma	MT
07/07	Genmab rebounds on a European Commission decision
07/07	EU approves expanded use of Genmab's Tepkinly	FW
07/07	Genmab Wins EU Approval for Follicular Lymphoma Treatment Combination	MT
06/07	Genmab Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma	GL
06/07	Genmab Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma	BU
06/07	Genmab Announces Tepkinly in Combination with Lenalidomide and Rituximab Is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma	CI
06/07	BNP Paribas raises the target price for Genmab to 2,500 Danish kroner (2,400), reiterates outperform - BN	FW
30/06	Genmab hit a Phase 3 endpoint with epcoritamab in lymphoma	FW
30/06	Genmab Says Epcoritamab Combo Improves Progression-free Survival in Phase 3 Blood Cancer Study	MT
30/06	Genmab Says Epcoritamab Combination Boosts Progression-Free Survival in Phase 3 Lymphoma Trial	MT
30/06	Genmab Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma, Demonstrating Statistically Significant Improvement in Progression-Free Survival	BU
30/06	Genmab Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma, Demonstrating Statistically Significant Improvement in Progression-Free Survival	GL
30/06	Genmab Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Demonstrating Statistically Significant Improvement in Progression-Free Survival	CI
24/06	AlphaValue/Baader Europe Reduces EPS Estimates for Genmab on Merger Financing Costs	MT
23/06	Genmab: Financing weighs now, pipeline pays later
17/06	Genmab A/S : has published its Articles of Association	PU
17/06	Capital Increase in Genmab as a Result of Employee Warrant Exercise	GL
17/06	Capital Increase in Genmab as a Result of Employee Warrant Exercise	AQ
15/06	Major Shareholder Announcement	GL
15/06	Major Shareholder Announcement	AQ
15/06	Genmab A/S : has published its Articles of Association	PU
13/06	Genmab Announces Epcoritamab Monotherapy and Epcoritamab-Based Combination Regimens Demonstrate High Response Rates in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)	BU
13/06	Genmab Announces Epcoritamab Monotherapy and Epcoritamab-Based Combination Regimens Demonstrate High Response Rates in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)	GL
13/06	Genmab Announces Epcoritamab Monotherapy And Epcoritamab-Based Combination Regimens Demonstrate High Response Rates In Elderly Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma	CI